222 related articles for article (PubMed ID: 38564259)
21. Improved Delineation of Colorectal Cancer Molecular Subtypes and Functional Profiles with a 62-Gene Panel.
Bhukdee D; Nuwongsri P; Israsena N; Sriswasdi S
Mol Cancer Res; 2023 Mar; 21(3):240-252. PubMed ID: 36490322
[TBL] [Abstract][Full Text] [Related]
22. Functional proteomics of colon cancer Consensus Molecular Subtypes.
Feliu J; Gámez-Pozo A; Martínez-Pérez D; Pérez-Wert P; Matamala-Luengo D; Viñal D; Kunz L; López-Vacas R; Dittmann A; Rodríguez-Salas N; Custodio A; Fresno Vara JÁ; Trilla-Fuertes L
Br J Cancer; 2024 Jun; 130(10):1670-1678. PubMed ID: 38486123
[TBL] [Abstract][Full Text] [Related]
23. Subtype-specific kinase dependency regulates growth and metastasis of poor-prognosis mesenchymal colorectal cancer.
Buikhuisen JY; Gomez Barila PM; Cameron K; Suijkerbuijk SJE; Lieftink C; di Franco S; Krotenberg Garcia A; Uceda Castro R; Lenos KJ; Nijman LE; Torang A; Longobardi C; de Jong JH; Dekker D; Stassi G; Vermeulen L; Beijersbergen RL; van Rheenen J; Huveneers S; Medema JP
J Exp Clin Cancer Res; 2023 Mar; 42(1):56. PubMed ID: 36869386
[TBL] [Abstract][Full Text] [Related]
24. Biomarker-guided therapy for colorectal cancer: strength in complexity.
Sveen A; Kopetz S; Lothe RA
Nat Rev Clin Oncol; 2020 Jan; 17(1):11-32. PubMed ID: 31289352
[TBL] [Abstract][Full Text] [Related]
25. Downregulation of mitochondrial complex I induces ROS production in colorectal cancer subtypes that differently controls migration.
Bastin J; Sroussi M; Nemazanyy I; Laurent-Puig P; Mouillet-Richard S; Djouadi F
J Transl Med; 2023 Aug; 21(1):522. PubMed ID: 37533102
[TBL] [Abstract][Full Text] [Related]
26. Molecular and clinicopathological differences between depressed and protruded T2 colorectal cancer.
Mochizuki K; Kudo SE; Kato K; Kudo K; Ogawa Y; Kouyama Y; Takashina Y; Ichimasa K; Tobo T; Toshima T; Hisamatsu Y; Yonemura Y; Masuda T; Miyachi H; Ishida F; Nemoto T; Mimori K
PLoS One; 2022; 17(10):e0273566. PubMed ID: 36264865
[TBL] [Abstract][Full Text] [Related]
27. Increasing Embryonic Morphogen Nodal Expression Suggests Malignant Transformation in Colorectal Lesions and as a Potential Marker for CMS4 Subtype of Colorectal Cancer.
Wang X; Liu S; Cao H; Li X; Rong Y; Liu G; Du H; Shen H
Pathol Oncol Res; 2021; 27():587029. PubMed ID: 34257534
[TBL] [Abstract][Full Text] [Related]
28. Relative contribution of clinicopathological variables, genomic markers, transcriptomic subtyping and microenvironment features for outcome prediction in stage II/III colorectal cancer.
Dienstmann R; Villacampa G; Sveen A; Mason MJ; Niedzwiecki D; Nesbakken A; Moreno V; Warren RS; Lothe RA; Guinney J
Ann Oncol; 2019 Oct; 30(10):1622-1629. PubMed ID: 31504112
[TBL] [Abstract][Full Text] [Related]
29. Associations of non-pedunculated T1 colorectal adenocarcinoma outcome with consensus molecular subtypes, immunoscore, and microsatellite status: a multicenter case-cohort study.
Haasnoot KJC; Backes Y; Moons LMG; Kranenburg O; Trinh A; Vermeulen L; Noë M; Tuynman JB; van Lent AUG; van Ginneken R; Seldenrijk CA; Raicu MG; Trumpi K; Ubink I; Milne AN; Boonstra JJ; Groen JN; Schwartz MP; Wolfhagen FHJ; Geesing JMJ; Ter Borg F; Brosens LAA; van Bergeijk J; Spanier BWM; de Vos Tot Nederveen Cappel WH; Kessels K; Seerden TCJ; Vleggaar FP; Offerhaus GJA; Siersema PD; Elias SG; Laclé MM;
Mod Pathol; 2020 Dec; 33(12):2626-2636. PubMed ID: 32581367
[TBL] [Abstract][Full Text] [Related]
30. High Expression of LTBP2 Contributes to Poor Prognosis in Colorectal Cancer Patients and Correlates with the Mesenchymal Colorectal Cancer Subtype.
Huang Y; Wang G; Zhao C; Geng R; Zhang S; Wang W; Chen J; Liu H; Wang X
Dis Markers; 2019; 2019():5231269. PubMed ID: 30956730
[TBL] [Abstract][Full Text] [Related]
31. Colorectal premalignancy is associated with consensus molecular subtypes 1 and 2.
Chang K; Willis JA; Reumers J; Taggart MW; San Lucas FA; Thirumurthi S; Kanth P; Delker DA; Hagedorn CH; Lynch PM; Ellis LM; Hawk ET; Scheet PA; Kopetz S; Arts J; Guinney J; Dienstmann R; Vilar E
Ann Oncol; 2018 Oct; 29(10):2061-2067. PubMed ID: 30412224
[TBL] [Abstract][Full Text] [Related]
32. Phenotypic subtypes predict outcomes in colorectal cancer.
Kasurinen J; Beilmann-Lehtonen I; Kaprio T; Hagström J; Haglund C; Böckelman C
Acta Oncol; 2023 Mar; 62(3):245-252. PubMed ID: 36867078
[TBL] [Abstract][Full Text] [Related]
33. Molecular subtyping of colorectal cancer: Recent progress, new challenges and emerging opportunities.
Wang W; Kandimalla R; Huang H; Zhu L; Li Y; Gao F; Goel A; Wang X
Semin Cancer Biol; 2019 Apr; 55():37-52. PubMed ID: 29775690
[TBL] [Abstract][Full Text] [Related]
34. [Characterization of patients with sporadic colorectal cancer following the new Consensus Molecular Subtypes (CMS)].
Wielandt AM; Villarroel C; Hurtado C; Simian D; Zamorano D; Martínez M; Castro M; Vial MT; Kronberg U; López-Kostner F
Rev Med Chil; 2017 Apr; 145(4):419-430. PubMed ID: 28748988
[TBL] [Abstract][Full Text] [Related]
35. Molecular-Subtype-Specific Biomarkers Improve Prediction of Prognosis in Colorectal Cancer.
Bramsen JB; Rasmussen MH; Ongen H; Mattesen TB; Ørntoft MW; Árnadóttir SS; Sandoval J; Laguna T; Vang S; Øster B; Lamy P; Madsen MR; Laurberg S; Esteller M; Dermitzakis ET; Ørntoft TF; Andersen CL
Cell Rep; 2017 May; 19(6):1268-1280. PubMed ID: 28494874
[TBL] [Abstract][Full Text] [Related]
36. CSRP1 expression is associated with a mesenchymal, stroma-rich tumor profile and poor prognosis in colon cancer.
Demirkol Canli S
Turk J Med Sci; 2023; 53(6):1678-1689. PubMed ID: 38813484
[TBL] [Abstract][Full Text] [Related]
37. Correlation of Immunological and Histopathological Features with Gene Expression-Based Classifiers in Colon Cancer Patients.
van de Weerd S; Smit MA; Roelands J; Mesker WE; Bedognetti D; Kuppen PJK; Putter H; Tollenaar RAEM; Roodhart JML; Hendrickx W; Medema JP; van Krieken JHJM
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293565
[TBL] [Abstract][Full Text] [Related]
38. A Transcription Factor Signature Can Identify the CMS4 Subtype and Stratify the Prognostic Risk of Colorectal Cancer.
Zhong ME; Huang ZP; Wang X; Cai D; Li CH; Gao F; Wu XJ; Wang W
Front Oncol; 2022; 12():902974. PubMed ID: 35847938
[TBL] [Abstract][Full Text] [Related]
39. Clinical management of metastatic colorectal cancer in the era of precision medicine.
Ciardiello F; Ciardiello D; Martini G; Napolitano S; Tabernero J; Cervantes A
CA Cancer J Clin; 2022 Jul; 72(4):372-401. PubMed ID: 35472088
[TBL] [Abstract][Full Text] [Related]
40. Association of Epigenetic Clock with Consensus Molecular Subtypes and Overall Survival of Colorectal Cancer.
Zheng C; Li L; Xu R
Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1720-1724. PubMed ID: 31375479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
